Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.75
MACK's Cash to Debt is ranked lower than
83% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. MACK: 0.75 )
Ranked among companies with meaningful Cash to Debt only.
MACK' s 10-Year Cash to Debt Range
Min: 0.75  Med: 81.89 Max: No Debt
Current: 0.75
Equity to Asset -1.02
MACK's Equity to Asset is ranked lower than
97% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MACK: -1.02 )
Ranked among companies with meaningful Equity to Asset only.
MACK' s 10-Year Equity to Asset Range
Min: -4.85  Med: -0.57 Max: 0.24
Current: -1.02
-4.85
0.24
F-Score: 3
Z-Score: -6.08
M-Score: -4.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -69.59
MACK's Operating margin (%) is ranked higher than
50% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. MACK: -69.59 )
Ranked among companies with meaningful Operating margin (%) only.
MACK' s 10-Year Operating margin (%) Range
Min: -2220.11  Med: -239.28 Max: -64.48
Current: -69.59
-2220.11
-64.48
Net-margin (%) -86.52
MACK's Net-margin (%) is ranked lower than
54% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. MACK: -86.52 )
Ranked among companies with meaningful Net-margin (%) only.
MACK' s 10-Year Net-margin (%) Range
Min: -2284.59  Med: -239.15 Max: -81.06
Current: -86.52
-2284.59
-81.06
ROA (%) -58.81
MACK's ROA (%) is ranked lower than
74% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. MACK: -58.81 )
Ranked among companies with meaningful ROA (%) only.
MACK' s 10-Year ROA (%) Range
Min: -110.9  Med: -76.70 Max: -47.45
Current: -58.81
-110.9
-47.45
ROC (Joel Greenblatt) (%) -499.15
MACK's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. MACK: -499.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MACK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1458.87  Med: -1218.12 Max: -468.88
Current: -499.15
-1458.87
-468.88
Revenue Growth (3Y)(%) -31.30
MACK's Revenue Growth (3Y)(%) is ranked lower than
76% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. MACK: -31.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MACK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -36.20 Max: -31.3
Current: -31.3
EBITDA Growth (3Y)(%) -55.30
MACK's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. MACK: -55.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MACK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -55.30 Max: -32.8
Current: -55.3
EPS Growth (3Y)(%) -51.40
MACK's EPS Growth (3Y)(%) is ranked lower than
92% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. MACK: -51.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MACK' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -51.40 Max: -33.8
Current: -51.4
» MACK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MACK Guru Trades in Q2 2014

Jim Simons 569,413 sh (New)
Paul Tudor Jones 13,622 sh (New)
Murray Stahl 12,000 sh (unchged)
» More
Q3 2014

MACK Guru Trades in Q3 2014

Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 321,213 sh (-43.59%)
» More
Q4 2014

MACK Guru Trades in Q4 2014

Paul Tudor Jones 12,196 sh (New)
Murray Stahl 12,000 sh (unchged)
Jim Simons 255,413 sh (-20.48%)
» More
Q1 2015

MACK Guru Trades in Q1 2015

Joel Greenblatt 13,433 sh (New)
Murray Stahl 19,000 sh (+58.33%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 476.19
MACK's Forward P/E is ranked lower than
96% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. MACK: 476.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/S 10.10
MACK's P/S is ranked higher than
53% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. MACK: 10.10 )
Ranked among companies with meaningful P/S only.
MACK' s 10-Year P/S Range
Min: 1.79  Med: 9.86 Max: 16.53
Current: 10.1
1.79
16.53
Current Ratio 0.96
MACK's Current Ratio is ranked lower than
89% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. MACK: 0.96 )
Ranked among companies with meaningful Current Ratio only.
MACK' s 10-Year Current Ratio Range
Min: 0.96  Med: 2.33 Max: 4.51
Current: 0.96
0.96
4.51
Quick Ratio 0.96
MACK's Quick Ratio is ranked lower than
85% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. MACK: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
MACK' s 10-Year Quick Ratio Range
Min: 0.96  Med: 2.33 Max: 4.51
Current: 0.96
0.96
4.51
Days Sales Outstanding 14.83
MACK's Days Sales Outstanding is ranked higher than
88% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. MACK: 14.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
MACK' s 10-Year Days Sales Outstanding Range
Min: 11.77  Med: 68.23 Max: 300.77
Current: 14.83
11.77
300.77

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.03
MACK's Price/Median PS Value is ranked higher than
55% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. MACK: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
MACK' s 10-Year Price/Median PS Value Range
Min: 0.19  Med: 1.11 Max: 1.35
Current: 1.03
0.19
1.35
Earnings Yield (Greenblatt) (%) -6.40
MACK's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MACK: -6.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MACK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -8.5  Med: 0.00 Max: 0
Current: -6.4
-8.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MP6.Germany,
Merrimack Pharmaceuticals Inc was incorporated in the Commonwealth of Massachusetts in 1993 and reincorporated under the laws of the State of Delaware in October 2010. The Company is a biopharmaceutical company engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. Its core approach to systems biology is to apply multidisciplinary and multi technology capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks, that allow to engineer treatments that are directed at the mechanisms of disease. The Company currently has six targeted therapeutic oncology candidates in clinical development, are either monoclonal antibodies or monoclonal antibody-derived molecules that are designed to block oncogenic signaling pathways, such as MM-121, MM-111, MM-151 and MM-141, or nanotherapeutics, such as MM-398 and MM-302, that are designed to preferentially deliver cytotoxic therapies to the tumor tissue. MM-398 is a novel, stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors. Its Phase 3 clinical trial of MM-398 is focused on pancreatic cancer, and used in a number of other solid tumor indications, including colorectal cancer, lung cancer, breast cancer, glioma and pediatric solid tumors. Its MM-121 is a fully human monoclonal antibody that targets the ErbB3 cell surface receptor. MM-121 is designed to inhibit cancer growth directly, restore a tumor's sensitivity to drugs to which it has become resistant, and delay the development of resistance by a tumor to other agents. Its MM-111 is a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell surface receptor. MM-111 is designed to anchor to both receptors, ErbB2 (HER2) and HER3, on the cell surface and block heregulin's ability to transmit tumor growth signals, thus inhibiting the tumor cell's ability to thrive. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. It is designed to target and bind to cancer cells that overexpress ErbB2 (HER2) and thereby release doxorubicin at the site of the tumor, while minimizing uptake into normal cells, including those of the heart. MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of EGFR (ErbB1). MM-151 is in its Phase 1 clinical trial for patients with refractory solid tumors. Its MM-141 is a fully human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jul 13 2015
Baxter's MAA for MM-398 Accepted in International Markets - Analyst Blog Jun 29 2015
MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the... Jun 25 2015
3 Stocks Spiking on Unusual Volume Jun 25 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application Jun 25 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application Jun 25 2015
Should You Buy Merrimack Pharmaceuticals Inc (MACK) After The 10% Surge? Jun 19 2015
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 16 2015
Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to... Jun 15 2015
Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to... Jun 15 2015
Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with... Jun 11 2015
Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with... Jun 11 2015
Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing... Jun 01 2015
Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing... Jun 01 2015
MERRIMACK PHARMACEUTICALS INC Financials May 15 2015
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... May 14 2015
Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology... May 14 2015
Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology... May 14 2015
Lightning Round: Don't know why this is so cheap May 13 2015
Merrimack Pharmaceuticals' Q1 Loss Wider Than Expected - Analyst Blog May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK